Avacta Group Share News (AVCT)
AVCT Share
AVCT Share
AVCT Share
AVCT Share
AVCT
AVCT Share
AVCT Level 2
AVCT Live
AVCT Broker
AVCT Directors
AVCT Financial
AVCT
AVCT Short
AVCT
Last checked at -
Mon, 13th Mar 2023 10:08
(Sharecast News) - Life science company Avacta reassured the market on Monday, following the collapse of technology and science-focussed Silicon Valley Bank last week.
The AIM-traded form said it had no banking relationship with either SVB or its local operation SVB UK.
As a result, it had no cash on deposit with them.
At 0951 GMT, shares in Avacta Group were down 1.34% at 135.66p.
Reporting by Josh White for Sharecast.com.
(Sharecast News) - Biotherapeutics developer Avacta Group has entered into a commercial partnership with Mologic, it announced on Monday, to accelerate to market its 'AffiDX' SARS-CoV-2 lateral flow rapid antigen test.
Read more
AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well
Read moreAvacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test
Read moreTRADING UPDATES: Asiamet Hits Back At Shareholder; Hardide Raises Cash
Read more(Sharecast News) - Biotherapeutics developer Avacta Group announced on Monday that its joint venture with Daewoong Pharmaceutical, AffyXell Therapeutics, has closed a series A venture capital investment of $7.3m (£5.32m) to further develop its pipeline of next generation cell and gene therapies.
Read moreIN BRIEF: Avacta Lands Deal With Bruker To Assess SARS-CoV-2 Test
Read moreIN BRIEF: Avacta Group Enters License Agreement With Point Biopharma
Read more(Sharecast News) - Cancer therapy and diagnostics developer Avacta Group has entered into a licence agreement with Point Biopharma, it announced on Thursday, to provide access to its 'preCISION' technology for the development of tumour-activated radiopharmaceuticals.
Read moreUK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost
Read more(Sharecast News) - Cancer therapy developer Avacta Group has submitted a clinical trial application in the UK for a phase 1 first-in-human open label dose-escalation and expansion study of its lead 'preCISION' prodrug, 'AVA6000', in patients with locally-advanced or metastatic selected solid tumours, it announced on Wednesday.
Read moreUK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain
Read more(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a licensing agreement with Astrea Bioseparations, it announced on Monday, for the use of the 'Affimer' platform in affinity purification applications.
Read more(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group announced "significant progress" in the development of a scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions on Monday.
Read moreUK DIRECTOR DEALINGS SUMMARY: Dunkerton Buys More Superdry Shares
Read moreIN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test
Read more
Last checked at